E
ExoMira Medicine develops MIRA-1, a first-in-class, dual-action small molecule inhibitor targeting the USP22 enzyme for pan-cancer therapy. This compound simultaneously triggers tumor cell apoptosis and reverses immune suppression within the tumor microenvironment. The resulting mechanism acts as both a direct cytotoxic agent and an immunotherapy to enhance T cell and NK cell activity against cancer.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- ExoMira Medicine develops MIRA-1, a first-in-class, dual-action small molecule inhibitor targeting the USP22 enzyme for pan-cancer therapy. This compound simultaneously triggers tumor cell apoptosis and reverses immune suppression within the tumor microenvironment. The resulting mechanism acts as both a direct cytotoxic agent and an immunotherapy to enhance T cell and NK cell activity against cancer.